Tandem Diabetes Care

Tandem Diabetes Care manufactures novel insulin pumps and software to improve diabetes management. Its key products include the touchscreen t:slim X2 pump that integrates with mobile apps, and the advanced t:slim X2 with Control-IQ technology which automatically adjusts insulin based on predicted glucose levels. 

Tandem's pumps aim to prevent high/low blood sugar and reduce the burden of manual insulin dosing. The company’s FDA-approved t:connect mobile app allows t:slim X2 insulin pump users to order bolus insulins through their smartphones, and, as of August 2022, had delivered one million boluses to users. 

Seeking to enhance its solutions, Tandem acquired infusion set developer Capillary Biomedical in 2022 to improve wearability and comfort. It also acquired insulin patch pump maker AMF Medical to expand its product portfolio.

The company began trading on Nasdaq in November 2013 under the ticker symbol “TNDM,” raising USD 120 million at IPO. For FY2023 , the company reported a revenue decline of 7% YoY to USD 747.7 million, as net losses for the year increased significantly to USD 233.2 million. In terms of guidance for 2024, Tandem provided its non-GAAP sales expectations to USD 850 million, implying an increase of 10% YoY.

Key customers and partnerships

In December 2023, the company partnered with Dexcom to integrate Dexcom's continuous glucose monitor with Tandem's t:slim X2 pump, enabling automated insulin delivery and dosing calculations. Furthermore, in October 2019, the company partnered with Abbott to develop and commercialize the t:slim X2 insulin pump, which combined Abbott's glucose sensing technology with Tandem's automated insulin delivery systems.